The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

What happened: Hims & Hers Health (HIMS) stock sank 15% in premarket.

What’s behind the move: The telehealth company reported a quarterly loss and sales that missed Wall Street expectations amid higher costs following the health platform's pivot to branded weight-loss medications.

First quarter revenue of $608 million came in below the consensus estimates of $617.5 million. The company posted a loss per share of $0.40, compared with a profit of $0.20 last year.

Hims & Hers pointed to $33.5 million in restructuring charges due to inventory write-downs and third-party costs as the company pivoted toward name-brand drugs.

What else you need to know: Hims & Hers Health stock has been recovering from a drawdown earlier this year, as regulatory and legal risks surrounding the manufacturing of compounded GLP-1 weight-loss drugs weighed on shares.

The company has been pivoting away from copycat weight-loss medications and toward partnerships with pharmaceutical manufacturers.

In March, Novo Nordisk (NVO) dropped its patent infringement lawsuit against the telehealth provider. Hims & Hers announced a collaboration with Novo Nordisk, saying it would provide GLP-1 customers with access to a broad assortment of FDA-approved medications and offer compounded semaglutide through the platform on a limited scale.

Ines Ferre is a senior business reporter for Yahoo Finance. Follow her on X at @ines_ferre.

Click here for in-depth analysis of the latest stock market news and events moving stock prices

Read the latest financial and business news from Yahoo Finance